← All diseases

Blood and immune system diseases

Congenital factor VII deficiency

An inherited bleeding disease in which factor VII, needed for blood clotting, is low. Severity varies greatly. Some people never have any bleeding.

Not part of the panel of Türkiye's National Newborn Screening Programme (heel-prick test). Source

Prepare an emergency card

This page is translated from the Turkish original.

This disease is followed through the “Blood and immune system diseases” group.

Understanding the disease

This section has not yet been reviewed by a physician. It summarises patient information from sources such as MedlinePlus, Orphanet and the NHS in plain language. The disease can differ from person to person; talk to your doctor about diagnosis and treatment.

What happens in this disease?

Clotting is a chain in which many proteins work in turn. Factor VII is one link in this chain. A change in the F7 gene leads to a fall in this protein. The blood cannot clot normally, and bleeding can last a long time. Surprisingly, in some people the opposite happens and clots can form inside blood vessels.

Which symptoms can occur?

Symptoms can begin at any age. The most severe cases are noticed in infancy. Up to a third of patients never have a bleeding problem.

  • Nosebleeds (common)
  • Bleeding gums (common)
  • Easy bruising (common)
  • Prolonged bleeding after surgery or injury
  • Heavy or long menstrual periods
  • Bleeding into the joints or blood in the urine (sometimes)
  • Bleeding inside the head or in the stomach and gut (in severe cases)
  • Blood clots inside blood vessels (in some people)

How is it diagnosed?

Among the clotting tests, the prothrombin time is long and the other test is normal. A test that measures the factor VII level in the blood confirms the diagnosis. A genetic test can show the change in the F7 gene.

Treatment and care

When there is bleeding or before surgery, the missing factor is replaced. There is an approved factor treatment for this. Medicines that stop a clot from breaking down too early also help. For people who have had bleeding in a joint or the brain, regular preventive treatment may be considered. Hormone treatment may be used for heavy menstrual bleeding. It is recommended that care be planned at a bleeding disorders center. The doctor who follows the disease decides which treatment is suitable.

For the family: inheritance and genetic counselling

The inborn type is passed on through recessive inheritance. The mother and father are carriers but usually have no symptoms. For a couple who are both carriers, the chance of having an affected child is 1 in 4 in each pregnancy. Recessive diseases may be more common in marriages between relatives. The type that appears later in life for reasons such as liver disease is not inherited. Genetic counselling guides the family.

Source: MedlinePlus Genetics: Factor VII deficiency · NORD: Factor VII Deficiency

Key facts

How common is it?
Prevalence: 1-9 per 1 000 000 (Europe)
When does it usually start?
Any age
Gene(s) involved
F7

These facts are taken from Orphanet and MedlinePlus records (last checked: October 7, 2026). Frequency values are approximate ranges.

You are not alone: patient associations in Türkiye

Non-profit patient and family organizations in Türkiye working on this disease or disease group. Links are for information; Doktorclub is not affiliated with these organizations and does not endorse them.

We could not find a patient association specific to this disease.

For all rare diseases: Nadir Hastalıklar Federasyonu

Support and help

Doktorclub does not diagnose, recommend treatments or refer you to hospitals or doctors. These pages are meant to help you talk with your doctor.

News about FVII deficiency

Clinical trials (ClinicalTrials.gov)

A clinical trial is a regulated study that tests whether a new treatment is safe and whether it works, in patients who volunteer. Most trials look for a certain age, genetic change and health condition. Taking part is voluntary.

This list is not a treatment recommendation. Treatments tested in phase 1–3 trials are investigational (experimental): their efficacy and safety have not yet been proven and they are not approved treatments. Taking part depends on each trial’s criteria and a physician’s assessment; the first step is to talk to the doctor who manages your care.

Questions you can ask your doctor

  • Could this trial be suitable for us?
  • If we take part, how would current treatment and check-ups be affected?
  • Where does the trial take place, and how are travel and accommodation handled?
  • What happens if we want to leave the trial?

ClinicalTrials.gov lists 5 active interventional studies for this disease. 3 are recruiting now; none has a site in Türkiye. Last checked: October 7, 2026.

Selected records (studies with a site in Türkiye first):

See all studies on ClinicalTrials.gov · Joining clinical trials

Blood and immune system diseases: other news

Medical codes (for talking with your doctor and finding sources)

These codes identify the disease in international classifications and databases. They can help when you talk with your doctor or look for reliable sources.

Orphanet code: ORPHA:327

No separate ICD-11 code; WHO classifies this disease under: 3B14.Z

Codes checked against WHO ICD-11 and Orphanet on October 7, 2026.

This page provides general information and does not replace diagnosis or treatment. Talk to your doctor about symptoms, diagnosis and treatment.

The information on these pages is for general information only and does not replace medical advice. Talk to your doctor about diagnosis and treatment decisions. In an emergency in Türkiye, call 112.

Every update is based on an open source and labeled with its level of evidence. No advertising and no drug brand names. Our scientific principles

This page was translated from Turkish by the Doktorclub editorial team.